GlassScriptPhysician profile
Gloria J Brelage
NPI 1063681021
$2,357.50
in general payments reported to CMS, 2019-2025
29 companies · $1,115 in 2025
The $1,115 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $40.11 · 2022: $17.33 · 2023: $572 · 2024: $490 · 2025: $1,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,105 · Education: $71.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,105.46 |
| Education | $71.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $466.20 | 2019-2025 | |
| Novo Nordisk INC | $376.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Vanda Pharmaceuticals INC. | $219.89 | 2025 | Fanapt |
| Exact Sciences Corporation | $196.27 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $132.10 | 2023-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $121.20 | 2023-2025 | Trintellix, Gattex |
| Astrazeneca Pharmaceuticals LP | $103.64 | 2019-2025 | Farxiga |
| Amgen INC. | $96.55 | 2023-2025 | Prolia, Evenity, Otezla |
| Glaxosmithkline, LLC. | $71.84 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $56.83 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $56.39 | 2023 | Verquvo, Belsomra, Steglatro |
| Abbvie INC. | $53.92 | 2023-2024 | Linzess, Viberzi |
| Xeris Pharmaceuticals, INC. | $49.12 | 2023-2024 | Gvoke Hypopen |
| Corium, LLC | $47.90 | 2025 | Azstarys |
| Biogen, INC. | $46.31 | 2025 | Zurzuvae |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $36.14 | 2024-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $32.27 | 2025 | Mounjaro, Zepbound |
| Daiichi Sankyo INC. | $24.63 | 2025 | Injectafer |
| Collegium Pharmaceutical, INC. | $18.94 | 2025 | Jornay Pm |
| Inspire Medical Systems, INC. | $18.45 | 2025 | Inspire |
| Shire North American Group INC | $18.41 | 2019 | |
| Cranial Technologies, INC | $16.74 | 2024 | Doc Band |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.49 | 2024 | Xifaxan, Trulance |
| Abiomed | $15.73 | 2025 | |
| Verona Pharma, INC. | $15.37 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $13.55 | 2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $12.51 | 2020 | |
| Grifols USA, LLC | $12.05 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gloria Brelage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.